Please login to the form below

Not currently logged in
Email:
Password:

MedImmune licenses reverse genetics technology to Novartis

MedImmune licenses its reverse genetics intellectual property to Novartis to support the development and construction of new vaccine strains

MedImmune, a subsidiary of AstraZeneca, has licensed its proprietary reverse genetics intellectual property to Novartis to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic influenza vaccines.

Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. It is a useful technology for prospective pandemic influenza vaccines, as the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, but rather segments of the virus's genome.

As the owner and exclusive licensee of the key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune says it is committed to ensuring the technology is accessible to varied government institutions and industry manufacturers. The company is therefore offering other influenza vaccine manufacturers non-exclusive licenses to this intellectual property estate for use in the manufacturing of seasonal or pandemic vaccines.

This deal marks the third reverse genetics licensing agreement that MedImmune has entered into with leaders in influenza vaccine development and manufacturing.

MedImmune will receive an upfront payment from Novartis and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

30th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics